Parkinson's Disease
In this condition, degenerative changes are found in an
area of the brain known as the substantia nigra, which
produces dopamine, a chemical substance that enables
people to move normally and smoothly. In Parkinson's
there's a severe lack of dopamine, which causes the main
symptoms - tremor, rigidity, and slowness of movement (bradykinesia).
Novartis Pharmaceuticals Corporation is currently seeking
patients to participate in the following
clinical trials. Please review the description(s) of the
clinical trial(s) listed below and click on the one that best
suits your condition.
When you click on a study, you will be presented with a
questionnaire to see if you (or the patient for whom you are
answering) meet the preliminary qualifications for this study.
If you or the patient meet these qualifications, a list of
participating study centers will be displayed. Select the study
center nearest you (or the patient) for additional information
about this clinical trial.
All clinical trial participants will be required to sign an
informed consent with the study center prior to enrolling in
the study. Novartis recommends that you consult your doctor
before participating in a clinical trial.
Parkinson’s Disease Study CELC200AUS11
Novartis Pharmaceuticals Corporation is conducting a
clinical research study to test the effectiveness of an
investigational drug on changes in motor symptoms and
quality of life in patients who have Parkinson’s
disease. This investigational drug is for people who are
taking carbidopa/levodopa medicine which has begun to
lose its effect. In order to take part in this study,
you must be between 30 and 80 years old and diagnosed
with Parkinson’s disease.
Trial phase: Phase 4
Participation Durations: 5 office visits to the
Study Doctor and 2 phone contacts over a 4 month period.
Protocol Number: CELC200AUS11
Parkinson’s Disease Study CELC200A2305
Novartis Pharmaceuticals Corporation is conducting a
clinical research trial for those who have been diagnosed
with early Parkinson’s disease, and who are not currently
receiving levodopa treatment. The purpose of this study is
to find out if the combination of carbidopa/levodopa/entacapone
provides greater benefit than the combination of carbidopa/levodopa
in treating the symptoms of early Parkinson’s disease. The
medications used in this study treat the symptoms of
Parkinson’s disease, they are not a cure for the disease.
Trial phase: Phase 3
Participation Durations: 39 weeks
Protocol Number: CELC200A2305
A Clinical Trials Site for Parkinson's
|
